Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCION: Durvalumab and SABR in Early Stage NSCLC
NCT04944173Phase 2Withdrawn
- Sponsor
- University of British Columbia
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University of British Columbia. Planned start Aug 2023; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04944173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944173.